Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 29, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Recombinant Proteins Market revenue to hit USD 9 Billion by 2035, says Research Nester
January 25, 2024 05:30 ET
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global recombinant proteins market size is slated to expand at ~12.80% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 9...
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
January 23, 2024 08:00 ET
|
ProPhase Labs, Inc.
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets
January 08, 2024 08:00 ET
|
Gallant Therapeutics
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
January 04, 2024 08:00 ET
|
ProPhase Labs, Inc.
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden...
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
January 03, 2024 08:00 ET
|
Wugen
Wugen Strengthens Executive Leadership Team with the Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
December 21, 2023 16:00 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Appointment of Chief Business Officer
December 19, 2023 07:00 ET
|
Avacta Group
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical...
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
December 11, 2023 15:00 ET
|
Wugen
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis
December 06, 2023 08:19 ET
|
Gallant Therapeutics
Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis